Boston Scientific (NYSE:BSX) issued an update on its FY 2019 earnings guidance on Wednesday morning. The company provided EPS guidance of $1.53-1.58 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.58. The company issued revenue guidance of $10.511-10.707 billion, compared to the consensus revenue estimate of $10.66 billion.Boston Scientific also updated its Q1 2019 guidance to $0.35-0.36 EPS.
A number of equities analysts have commented on the stock. Oppenheimer set a $38.00 target price on shares of Boston Scientific and gave the stock a hold rating in a research note on Wednesday, October 24th. Zacks Investment Research downgraded shares of Boston Scientific from a hold rating to a sell rating in a research note on Monday, December 31st. BTIG Research restated a buy rating and issued a $45.00 target price on shares of Boston Scientific in a research note on Thursday, October 25th. Stephens restated a market perform rating and issued a $40.00 target price on shares of Boston Scientific in a research note on Monday, November 19th. Finally, Needham & Company LLC restated a buy rating and issued a $43.00 target price on shares of Boston Scientific in a research note on Tuesday, January 8th. Three research analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $40.12.
Shares of BSX opened at $37.75 on Wednesday. Boston Scientific has a fifty-two week low of $25.04 and a fifty-two week high of $39.44. The company has a market capitalization of $52.24 billion, a PE ratio of 29.96, a price-to-earnings-growth ratio of 2.20 and a beta of 0.83. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.78 and a quick ratio of 0.56.
In other news, SVP Arthur C. Butcher sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $38.50, for a total value of $154,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Maulik Nanavaty sold 3,038 shares of the company’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $35.46, for a total transaction of $107,727.48. The disclosure for this sale can be found here. Insiders sold a total of 95,724 shares of company stock valued at $3,504,373 in the last ninety days. Corporate insiders own 0.73% of the company’s stock.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
See Also: Coverage Ratio
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.